LG LIFE SCIENCES, LTD. Patent applications |
Patent application number | Title | Published |
20160051558 | PHARMACEUTICAL COMPOSITION FOR INHIBITING IMMUNE RESPONSE THROUGH INDUCING DIFFERENTIATION INTO REGULATOR T CELLS AND PROMOTING PROLIFERATION OF REGULATOR T CELLS - The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells. | 02-25-2016 |
20160045497 | COMPLEX PREPARATION INCLUDING VALSARTAN AND ROSUVASTATIN CALCIUM AND MANUFACTURING METHOD THEREFOR - The present invention relates to a pharmaceutical composition including valsartan and rosuvastatin calcium as active ingredients, and a manufacturing method therefor. The pharmaceutical composition including valsartan and rosuvastatin calcium according to the present invention can alleviate side effects of the existing single preparations and simultaneously improve compliance of patients having a cardiovascular disease, a hyperlipidemic disease and a complex disease thereof, and increases treatment and prevention effects, and in particular, obtains synergistic effects in treating hyperlipidemia, and enhances the dissolution rate of valsartan and rosuvastatin calcium and treatment effects by granulating valsartan and mixing rosuvastatin calcium. | 02-18-2016 |
20150376173 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT - The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders. | 12-31-2015 |
20150309063 | AUTOMATIC IN VITRO DIAGNOSTIC APPARATUS INCLUDING INCLINED ROTATING PLATE - According to the present invention, an automatic in vitro diagnosis apparatus including an inclined rotating stirrer is an apparatus for the automatic in vitro diagnosis of a clinical specimen or a reagent. The present invention includes: a clinical specimen storage unit which stores a clinical specimen; a reagent storage unit which stores a reagent; a code reader unit which recognizes an identification code attached to the clinical specimen storage unit or to the reagent storage unit; a dispenser which suctions the clinical specimen and the reagent from the clinical specimen storage unit and the reagent storage unit, and transports the clinical specimen and the reagent which are suctioned; and a rotating stirrer which receives the clinical specimen and the reagent from the dispenser and rotates about an axis of rotation so as to stir the clinical specimen and the reagent. The axis of rotation of the rotating stirrer forms a predetermined angle with the direction of gravity, and a series of processes for storing, transporting, and stirring the clinical specimen and the reagent are integrated so as to maximize the efficiency of the stirring and the efficiency of the operations. | 10-29-2015 |
20150291585 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE - 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy. | 10-15-2015 |
20150291527 | THIOARYL DERIVATIVES AS GPR120 AGONISTS - The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis. | 10-15-2015 |
20140199303 | Stable Liquid Formulation of Etanercept - The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment. | 07-17-2014 |
20140127671 | Simultaneous Diagnosis Kit For a Disease Due to a Respiratory Virus - The present invention relates to a kit for simultaneous diagnosis of viral respiratory diseases. To be more specific, the present invention is directed to a method for diagnosing viral respiratory diseases by detecting the genes specific to the respiratory disease-causing virus, a primer set for diagnosing the viral respiratory diseases used in the diagnosis method, a composition for simultaneous diagnosis of viral respiratory diseases, comprising the primer set, and a kit for simultaneous diagnosis of viral respiratory diseases, comprising the composition. When the primer set of the present invention for diagnosing the viral respiratory diseases is used, 14 different types of respiratory viruses can be simultaneously detected only with one reaction through real-time multiplex reverse transcription (RT)-PCR, and the onset of respiratory diseases caused by these viruses can be diagnosed. Thus, the primer set of the present invention can be widely used for prompt diagnosis and treatment of respiratory diseases. | 05-08-2014 |
20140024618 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient. | 01-23-2014 |
20130324593 | Novel Hybrid Promoter and Recombinant Vector Comprising the Same - The present invention relates to a hybrid promoter, in which a whole or a part of a CMV enhancer, a whole or a part of a β-actin promoter, a whole or a part of a CMV promoter, and a whole or a part of a β-actin intron are operably linked to each other, a recombinant vector comprising the same, a transformant transformed with the recombinant vector, a pharmaceutical composition comprising the recombinant vector or the transformant, and a method for preparing a target protein using the recombinant vector or the transformant. The hybrid promoter of the present invention is able to induce high expression of a target protein in a eukaryotic cell. Therefore, the hybrid promoter of the present invention can be effectively used for the development of an antibody or the production of a DNA vaccine. | 12-05-2013 |
20130237532 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient. | 09-12-2013 |
20130210729 | NON-AQUEOUS OILY INJECTABLE FORMULATION EXHIBITING PRESERVATIVE EFFICACY - Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative. | 08-15-2013 |
20130203787 | HYDRATE OF 1--5,5-DIFLUORO-PIPERIDIN-2-ONE TARTRATE - The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis (trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-di-fluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component. | 08-08-2013 |
20130165659 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT - The present invention relates to a novel method for preparing a compound of formula (2) as the intermediate, which can be effectively used for preparation of a compound of formula (1) exhibiting good inhibitory activity against dipeptidyl peptidase IV enzyme. | 06-27-2013 |
20130147473 | DETECTION SYSTEM USING MAGNETIC RESISTANCE SENSOR - Provided is a detection system using a magnetic resistance sensor. The detection system includes a magnetic resistance sensor for detecting a magnetic element of a specimen containing a magnetic particle. An external magnetic-field application device applies external magnetic fields to the magnetic resistance sensor in first and second directions, and has a space for entrance or exit of a specimen holding unit. A horizontal drive module receives the specimen holding unit to horizontally move the specimen holding unit under the magnetic resistance sensor. A vertical drive module receives the magnetic resistance sensor to vertically move the magnetic resistance sensor to the specimen holding unit. | 06-13-2013 |
20130059751 | GENE FAMILY (LBFL313) ASSOCIATED WITH PANCREATIC CANCER - The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues. | 03-07-2013 |
20110224219 | MELANOCORTIN RECEPTOR AGONISTS - The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient. | 09-15-2011 |
20110201554 | HFSH AQUEOUS FORMULATION - Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time. | 08-18-2011 |
20110166356 | METHOD FOR PREPARING MONTELUKAST SODIUM SALTS - Disclosed is a method for preparing a montelukast sodium salt of Formula 1. The method includes coupling a methanesulfonyl compound of Formula 2 below with a compound of Formula 3 below in the presence of a bistrimethylsilylamide alkali metal salt, further adding an alkali metal base thereto and hydrolyzing the mixture by heating to prepare a compound of Formula 4 below, reacting the compound of Formula 4 with 4-tert-butylcyclohexylamine, followed by purification, to prepare an amine salt of Formula 5, and converting the amine salt of Formula 5 into a sodium salt. | 07-07-2011 |
20110166121 | FUSED HETEROCYCLIC COMPOUND - The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same. | 07-07-2011 |
20100274013 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE AGENT - Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent. | 10-28-2010 |
20100267708 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to new compounds of formula (1) exhibiting excellent activity for glucokinase, and pharmaceutical compositions comprising the same as an active ingredient. | 10-21-2010 |
20100210647 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient. | 08-19-2010 |
20100197673 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient. | 08-05-2010 |
20100173284 | Method for Detection of HCV at the Real Time PCR with Intercalating Dye - The present invention relates to a composition for detection of HCV by a single step reaction, comprising a specific primer and probe. In particular, the present invention relates to a composition for detection of HCV by a single step reaction, comprising the primer sequences of SEQ ID NOs:1 and 2; a composition for detection of HCV by a single step reaction, comprising both the primer sequences and a probe of SEQ ID NOs:5 or 9; a method for detecting HCV by a single step reaction, comprising the steps of obtaining a sample from a subject, and amplifying and detecting HCV using the primer and probe; and a kit comprising the primer and probe, in which the HCV detection method is characterized by a single step reaction. | 07-08-2010 |
20100120843 | PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL-INDUCED LIVER INJURY COMPRISING (4S,5S)-5-FLUOROMETHYL-5-HYDROXY-4-(AMINO)-DIHYDROFURAN-2-ONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition for treating alcohol-induced liver injury comprising (4S,5S)-5-fluoromethyl-5-hydroxy-4-({[(5R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof, and a use thereof. | 05-13-2010 |
20100041661 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD - The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 02-18-2010 |
20100036158 | NOVEL PROCESS FOR PREPARING 3-AMINO-5-FLUORO-4-DIALKOXYPENTANOIC ACID ESTER - The present invention relates to a novel process for the production of 3-amino-5-fluoro-4-dialkoxypentanoic acid ester used in the precursor of 3-amino-5-fluoro-4-oxopentanoic acid, represented by the following formula (1): wherein R1 and R2 are as defined in the Description. | 02-11-2010 |
20100016376 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD - The present invention relates to a pyridone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 01-21-2010 |
20090325904 | MALEIC ACID MONOSALT OF ANTIVIRAL AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3λ5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same. | 12-31-2009 |
20090291959 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD - The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same. | 11-26-2009 |
20090197347 | IMMUNOASSAY FOR PLASMODIUM FALCIPARUM AND ASSAY DEVICE USED THEREFOR - Disclosed are an immunoassay of | 08-06-2009 |
20090188000 | GENE FAMILY (LBFL313) ASSOCIATED WITH PANCREATIC CANCER - The invention relates generally to the changes in gene expression in human pancreatic adenocarcinoma. The invention relates specifically to a human gene family which is differentially expressed in cancerous pancreatic tissues compared to corresponding non-cancerous pancreatic tissues. | 07-23-2009 |
20090181050 | Manufacturing Method of Combined Vaccine - The present invention relates to a method for manufacturing a combined vaccine capable of concurrently preventing multiple diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in an infant. The method for manufacturing a combined vaccine according to the present invention includes the steps of independently adsorbing each protective antigen to an adsorbent of a aluminum hydroxide gel with respect to various diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in the infants, and combining each protective antigen adsorbed to the adsorbent after the adsorption. In the present invention, it is possible to concurrently prevent multiple diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in the infant using a combined vaccine manufactured according to the present invention. | 07-16-2009 |
20080260654 | Sustained Release Composition of Protein Drug - Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide. | 10-23-2008 |